APTEVO THERAPEUTICS INC (APVO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.74+1.75%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · APVO
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||
| Revenues | — | — | — | — | 3.1 | 12.3 | 4.3 | 32.4 | 23.1 | 14.7 | 10.0 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 14.7 | 10.0 |
| Cost of Revenues | — | — | — | — | — | — | — | 19.9 | — | — | — |
| Operating Expenses & Income | |||||||||||
| Selling, General & Admin | — | — | — | — | — | — | — | 25.3 | 28.1 | 34.6 | 36.2 |
| R&D Expenses | 15.2 | 14.5 | 14.4 | 17.1 | 17.9 | 19.0 | 17.9 | 24.8 | 35.4 | 29.0 | 29.1 |
| Operating Income | (26.9) | (26.3) | (24.6) | (28.9) | (28.6) | (21.4) | (27.5) | (41.0) | (51.7) | (53.9) | (138.8) |
| Earnings from Continuing Operations | |||||||||||
| Other Non-Operating Income / Expenses | — | — | — | — | — | — | — | — | — | (1.9) | (0.8) |
| Asset Writedown | — | — | — | — | — | — | — | — | — | 71.0 | 71.0 |
| EBT, Incl. Unusual Items | — | (26.0) | (24.1) | (18.7) | 7.0 | (29.4) | (30.9) | (43.1) | (53.7) | (55.9) | (139.6) |
| Income Tax Expense | — | — | — | — | — | — | — | — | (23.3) | (23.3) | (19.7) |
| Earnings from Continuing Operations | — | (26.0) | (24.1) | (18.7) | 7.0 | (29.4) | (30.9) | (43.1) | (53.7) | (32.6) | — |
| Net Income | |||||||||||
| Net Income | (26.4) | (26.0) | (24.1) | (17.4) | 8.0 | (28.5) | (17.8) | (40.4) | (53.7) | 7.0 | (112.4) |
| Per Share | |||||||||||
| Basic EPS | (22.07) | (87.27) | (87.38) | — | 1.57 | (6.07) | — | — | — | — | — |
| Diluted EPS | (22.07) | (87.27) | (87.38) | — | 1.57 | (6.07) | — | — | — | — | — |
| Basic Weighted Avg Shares | 1.2 | 0.3 | 0.3 | 0.0 | 5.1 | 4.7 | — | — | — | — | — |
| Diluted Weighted Avg Shares | 1.2 | 0.3 | 0.3 | 0.0 | 5.1 | 4.7 | — | — | — | — | — |
| Supplemental | |||||||||||
| EBITDA | — | (26.1) | (24.3) | (28.3) | (27.7) | (20.3) | (26.1) | (38.7) | (49.3) | (50.8) | (135.4) |
| EBIT | (26.9) | (26.3) | (24.6) | (28.9) | (28.6) | (21.4) | (27.5) | (41.0) | (51.7) | (53.9) | (138.8) |
| Effective Tax Rate | — | — | — | — | — | — | — | — | 43.4% | 41.7% | 14.1% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.